Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir
Background. Direct-acting antivirals (DAAs) made a drastic change in the management of HCV infection. Sofosbuvir is one of the highly potent DAAs, eliminated mainly through the kidney. But concerns about renal safety during treatment may limit its use. Neutrophil gelatinase-associated lipocalin (NGA...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Canadian Journal of Gastroenterology and Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2020/1632959 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832555105869627392 |
|---|---|
| author | Ali Nada Mohamed Abbasy Aliaa Sabry Azza Mohamed Abdu Allah Somaia Shehab-Eldeen Nada Elnaidany Hanan Elimam Kawthar Ibraheem Mohamed Ibraheem Abdallah Essa |
| author_facet | Ali Nada Mohamed Abbasy Aliaa Sabry Azza Mohamed Abdu Allah Somaia Shehab-Eldeen Nada Elnaidany Hanan Elimam Kawthar Ibraheem Mohamed Ibraheem Abdallah Essa |
| author_sort | Ali Nada |
| collection | DOAJ |
| description | Background. Direct-acting antivirals (DAAs) made a drastic change in the management of HCV infection. Sofosbuvir is one of the highly potent DAAs, eliminated mainly through the kidney. But concerns about renal safety during treatment may limit its use. Neutrophil gelatinase-associated lipocalin (NGAL) has been proven as a predictor of renal tubular injury. Hence, the aim of this work was to assess serum neutrophil gelatinase-associated lipocalin (NGAL) in HCV-positive patients before and after treatment with the sofosbuvir-based antiviral regimen. Methods. This prospective study included 87 Egyptian patients with chronic HCV infection treated with sofosbuvir plus daclatasvir with or without ribavirin for 12 weeks. Serum NGAL was measured before and at the end of treatment (EOT). Analysis of NGAL and estimated glomerular filtration rate (eGFR) evolution was done. Results. Our results showed a statistically significant decrease in serum NGAL (P=0.02) with a nonsignificant reduction in eGFR (P=0.06). Moreover, changes in serum NGAL levels (baseline compared to EOT) in patients ranked by KDIGO-CKD classification showed a significant decrease in stages 1 and 2 (P=0.14 and 0.034, respectively) and a nonsignificant decrease in stage 3 (P=0.25). Also, eGFR changes after treatment in patients ranked by the same classifications showed a nonsignificant reduction in all stages (P>0.05). Conclusions. Sofosbuvir appears to have no nephrotoxic effects and is safe to treat patients with chronic HCV infection. |
| format | Article |
| id | doaj-art-475bfdaebc8b4ce89ad19faba771f085 |
| institution | Kabale University |
| issn | 2291-2789 2291-2797 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology and Hepatology |
| spelling | doaj-art-475bfdaebc8b4ce89ad19faba771f0852025-02-03T05:49:32ZengWileyCanadian Journal of Gastroenterology and Hepatology2291-27892291-27972020-01-01202010.1155/2020/16329591632959Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with SofosbuvirAli Nada0Mohamed Abbasy1Aliaa Sabry2Azza Mohamed Abdu Allah3Somaia Shehab-Eldeen4Nada Elnaidany5Hanan Elimam6Kawthar Ibraheem Mohamed Ibraheem7Abdallah Essa8Hepatology Department, National Liver Institute, Menoufia University, Shebin-Elkom, EgyptHepatology Department, National Liver Institute, Menoufia University, Shebin-Elkom, EgyptHepatology Department, National Liver Institute, Menoufia University, Shebin-Elkom, EgyptBiochemistry and Molecular Biology Department, Faculty of Medicine, Menoufia University, Shebin-Elkom, EgyptTropical Medicine Department, Faculty of Medicine, Menoufia University, Shebin-Elkom, EgyptFaculty of Pharmacy, MSA University, 6th of October City, EgyptBiochemistry Department, Faculty of Pharmacy, University of Sadat City, Sadat City, EgyptMedical Microbiology and Immunology Department, Faculty of Medicine, Ain Shams University, Cairo, EgyptTropical Medicine Department, Faculty of Medicine, Menoufia University, Shebin-Elkom, EgyptBackground. Direct-acting antivirals (DAAs) made a drastic change in the management of HCV infection. Sofosbuvir is one of the highly potent DAAs, eliminated mainly through the kidney. But concerns about renal safety during treatment may limit its use. Neutrophil gelatinase-associated lipocalin (NGAL) has been proven as a predictor of renal tubular injury. Hence, the aim of this work was to assess serum neutrophil gelatinase-associated lipocalin (NGAL) in HCV-positive patients before and after treatment with the sofosbuvir-based antiviral regimen. Methods. This prospective study included 87 Egyptian patients with chronic HCV infection treated with sofosbuvir plus daclatasvir with or without ribavirin for 12 weeks. Serum NGAL was measured before and at the end of treatment (EOT). Analysis of NGAL and estimated glomerular filtration rate (eGFR) evolution was done. Results. Our results showed a statistically significant decrease in serum NGAL (P=0.02) with a nonsignificant reduction in eGFR (P=0.06). Moreover, changes in serum NGAL levels (baseline compared to EOT) in patients ranked by KDIGO-CKD classification showed a significant decrease in stages 1 and 2 (P=0.14 and 0.034, respectively) and a nonsignificant decrease in stage 3 (P=0.25). Also, eGFR changes after treatment in patients ranked by the same classifications showed a nonsignificant reduction in all stages (P>0.05). Conclusions. Sofosbuvir appears to have no nephrotoxic effects and is safe to treat patients with chronic HCV infection.http://dx.doi.org/10.1155/2020/1632959 |
| spellingShingle | Ali Nada Mohamed Abbasy Aliaa Sabry Azza Mohamed Abdu Allah Somaia Shehab-Eldeen Nada Elnaidany Hanan Elimam Kawthar Ibraheem Mohamed Ibraheem Abdallah Essa Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir Canadian Journal of Gastroenterology and Hepatology |
| title | Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir |
| title_full | Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir |
| title_fullStr | Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir |
| title_full_unstemmed | Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir |
| title_short | Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir |
| title_sort | serum neutrophil gelatinase associated lipocalin ngal in hcv positive egyptian patients treated with sofosbuvir |
| url | http://dx.doi.org/10.1155/2020/1632959 |
| work_keys_str_mv | AT alinada serumneutrophilgelatinaseassociatedlipocalinngalinhcvpositiveegyptianpatientstreatedwithsofosbuvir AT mohamedabbasy serumneutrophilgelatinaseassociatedlipocalinngalinhcvpositiveegyptianpatientstreatedwithsofosbuvir AT aliaasabry serumneutrophilgelatinaseassociatedlipocalinngalinhcvpositiveegyptianpatientstreatedwithsofosbuvir AT azzamohamedabduallah serumneutrophilgelatinaseassociatedlipocalinngalinhcvpositiveegyptianpatientstreatedwithsofosbuvir AT somaiashehabeldeen serumneutrophilgelatinaseassociatedlipocalinngalinhcvpositiveegyptianpatientstreatedwithsofosbuvir AT nadaelnaidany serumneutrophilgelatinaseassociatedlipocalinngalinhcvpositiveegyptianpatientstreatedwithsofosbuvir AT hananelimam serumneutrophilgelatinaseassociatedlipocalinngalinhcvpositiveegyptianpatientstreatedwithsofosbuvir AT kawtharibraheemmohamedibraheem serumneutrophilgelatinaseassociatedlipocalinngalinhcvpositiveegyptianpatientstreatedwithsofosbuvir AT abdallahessa serumneutrophilgelatinaseassociatedlipocalinngalinhcvpositiveegyptianpatientstreatedwithsofosbuvir |